

# Franz KÃ¶nig

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5694811/publications.pdf>

Version: 2024-02-01

125  
papers

5,322  
citations

81900

39  
h-index

91884

69  
g-index

139  
all docs

139  
docs citations

139  
times ranked

5165  
citing authors

#	ARTICLE	IF	CITATIONS
1	Testing and Interpreting the “Right-Hypothesis” Comment on “Non-proportional Hazards” An Evaluation of the MaxCombo Test in Cancer Clinical Trials” Statistics in Biopharmaceutical Research, 2023, 15, 310-311.	0.8	3
2	Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials. Pharmaceutical Statistics, 2022, 21, 671-690.	1.3	11
3	Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. Clinical Microbiology and Infection, 2022, 28, 596-601.	6.0	3
4	Assessing mechanical catheter dysfunction in automated tidal peritoneal dialysis using cyclor software: a case control, proof-of-concept study. Scientific Reports, 2022, 12, 5657.	3.3	0
5	Robust group sequential designs for trials with survival endpoints and delayed response. Biometrical Journal, 2022, 64, 343-360.	1.0	5
6	Monitoring Daily Ultrafiltration in Automated Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 107-110.	4.5	2
7	MO679: Peritonitis May Disrupt Cyclic Periodicity of Ultrafiltration in Peritoneal Dialysis. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
8	MO669: Predictive Parameters of Automated PD Cyclor Software for Diagnosis of Catheter Dysfunction. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
9	Selecting predictive biomarkers from genomic data. PLoS ONE, 2022, 17, e0269369.	2.5	1
10	Testing Procedures for Claiming Success on at Least k Out of m Hypotheses with an Application to Biosimilar Development. Statistics in Biopharmaceutical Research, 2021, 13, 106-112.	0.8	1
11	Are p-values Useful to Judge the Evidence Against the Null Hypotheses in Complex Clinical Trials? A Comment on “The Role of p-values in Judging the Strength of Evidence and Realistic Replication Expectations” Statistics in Biopharmaceutical Research, 2021, 13, 43-45.	0.8	2
12	Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology. Pharmaceutical Statistics, 2021, 20, 129-145.	1.3	14
13	Systematic review of available software for multi-arm multi-stage and platform clinical trial design. Trials, 2021, 22, 183.	1.6	18
14	Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs. Statistics in Medicine, 2021, 40, 2939-2956.	1.6	11
15	Analysis of Inflammatory Mediator Profiles in Sepsis Patients Reveals That Extracellular Histones Are Strongly Elevated in Nonsurvivors. Mediators of Inflammation, 2021, 2021, 1-13.	3.0	8
16	COVID-19 is not “just another flu”, a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria. Infection, 2021, 49, 907-916.	4.7	7
17	An international comparison of age and sex dependency of COVID-19 deaths in 2020: a descriptive analysis. Scientific Reports, 2021, 11, 19143.	3.3	42
18	Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study. Statistical Methods in Medical Research, 2020, 29, 1483-1498.	1.5	2

#	ARTICLE	IF	CITATIONS
19	A multiple comparison procedure for dose-finding trials with subpopulations. <i>Biometrical Journal</i> , 2020, 62, 53-68.	1.0	1
20	Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 773-779.	4.7	48
21	Endpoints for randomized controlled clinical trials for COVID-19 treatments. <i>Clinical Trials</i> , 2020, 17, 472-482.	1.6	55
22	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 483-497.	0.8	40
23	Commentary on Parker and Weir. <i>Clinical Trials</i> , 2020, 17, 567-569.	1.6	14
24	The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. <i>Trials</i> , 2020, 21, 528.	1.6	10
25	The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. <i>BMJ, The</i> , 2020, 369, m115.	6.0	57
26	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. <i>European Journal of Cancer</i> , 2020, 135, 150-158.	2.8	10
27	The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. <i>Clinical Therapeutics</i> , 2020, 42, 1330-1360.	2.5	74
28	Analysis of Austrian COVID-19 deaths by age and sex. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 685-689.	1.9	16
29	Single-reviewer abstract screening missed 13 percent of relevant studies: a crowd-based, randomized controlled trial. <i>Journal of Clinical Epidemiology</i> , 2020, 121, 20-28.	5.0	87
30	A critical review of graphics for subgroup analyses in clinical trials. <i>Pharmaceutical Statistics</i> , 2020, 19, 541-560.	1.3	12
31	Composite Outcome Improves Feasibility of Clinical Trials in Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2019, 39, 479-485.	2.3	2
32	Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations. <i>Pharmaceutical Statistics</i> , 2019, 18, 329-350.	1.3	7
33	Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. <i>Pharm Stat</i> 17(5):593-606, Sep/Oct 2018., DOI: <a href="https://doi.org/10.1002/pst.1873">https://doi.org/10.1002/pst.1873</a> . <i>Pharmaceutical Statistics</i> , 2019, 18, 284-286.	1.3	1
34	Interim analysis incorporating short- and long-term binary endpoints. <i>Biometrical Journal</i> , 2019, 61, 665-687.	1.0	12
35	Optimized adaptive enrichment designs. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2096-2111.	1.5	28
36	An update on the clinical evidence that supports biosimilar approvals in Europe. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1415-1431.	2.4	19

#	ARTICLE	IF	CITATIONS
37	Estimation after blinded sample size reassessment. <i>Statistical Methods in Medical Research</i> , 2018, 27, 1830-1846.	1.5	8
38	Marketing authorisation of orphan medicines in Europe from 2000 to 2013. <i>Drug Discovery Today</i> , 2018, 23, 424-433.	6.4	24
39	Sample Size for Multiple Hypothesis Testing in Biosimilar Development. <i>Statistics in Biopharmaceutical Research</i> , 2018, 10, 39-49.	0.8	8
40	Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. <i>BMC Medicine</i> , 2018, 16, 210.	5.5	28
41	Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency. <i>Trials</i> , 2018, 19, 642.	1.6	26
42	A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health. <i>Kidney International</i> , 2018, 94, 1227-1237.	5.2	45
43	Subgroup identification in clinical trials via the predicted individual treatment effect. <i>PLoS ONE</i> , 2018, 13, e0205971.	2.5	26
44	Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup. <i>Statistics in Medicine</i> , 2018, 37, 3387-3402.	1.6	8
45	Lessons learned from IDeAl – 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 77.	2.7	22
46	A proposal for a new PhD level curriculum on quantitative methods for drug development. <i>Pharmaceutical Statistics</i> , 2018, 17, 593-606.	1.3	6
47	SU0013ALANYL-GLUTAMINE IN PERITONEAL DIALYSIS FLUIDS IMPROVES PERITONEAL HEALTH AND SYSTEMIC INFLAMMATION: A DOUBLE-BLINDED RANDOMIZED CROSSOVER TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i621-i621.	0.7	0
48	Design and estimation in clinical trials with subpopulation selection. <i>Statistics in Medicine</i> , 2018, 37, 4335-4352.	1.6	18
49	Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection – Results of a Cross-Sectional Screening Study. <i>Transplantation</i> , 2017, 101, 631-641.	1.0	60
50	Clearance of Selected Plasma Cytokines with Continuous Veno-Venous Hemodialysis Using Ultraflux EMIc2 versus Ultraflux AV1000S. <i>Blood Purification</i> , 2017, 44, 260-266.	1.8	8
51	Multiple Test Strategies for Comparing Several Doses with a Control in Confirmatory Trials. , 2017, , 279-290.		1
52	Many-to-one comparisons after safety selection in multi-arm clinical trials. <i>PLoS ONE</i> , 2017, 12, e0180131.	2.5	2
53	Degeneration and Instability and the Relation to Patients'™ Function Late After Lumbar Disc Surgery. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2016, 95, 871-879.	1.4	6
54	Adaptive paediatric investigation plans, a small step to improve regulatory decision making in drug development for children?. <i>Pharmaceutical Statistics</i> , 2016, 15, 384-386.	1.3	3

#	ARTICLE	IF	CITATIONS
55	Evidence, eminence and extrapolation. <i>Statistics in Medicine</i> , 2016, 35, 2117-2132.	1.6	24
56	Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. <i>Statistics in Medicine</i> , 2016, 35, 325-347.	1.6	166
57	Clinical trials for authorized biosimilars in the European Union: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1444-1457.	2.4	21
58	“Threshold-crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 699-712.	4.7	61
59	Authors' response to comments. <i>Statistics in Medicine</i> , 2016, 35, 364-367.	1.6	1
60	Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials. <i>PLoS ONE</i> , 2016, 11, e0146465.	2.5	32
61	Optimizing Trial Designs for Targeted Therapies. <i>PLoS ONE</i> , 2016, 11, e0163726.	2.5	24
62	Sharing clinical trial data on patient level: Opportunities and challenges. <i>Biometrical Journal</i> , 2015, 57, 8-26.	1.0	60
63	Adaptive designs for subpopulation analysis optimizing utility functions. <i>Biometrical Journal</i> , 2015, 57, 76-89.	1.0	42
64	Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis. <i>Transplant International</i> , 2015, 28, 820-827.	1.6	14
65	The risks of methodology aversion in drug regulation. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 317-318.	46.4	13
66	Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. <i>Trials</i> , 2014, 15, 383.	1.6	64
67	ABO antibody and complement depletion by immunoabsorption combined with membrane filtration—a randomized, controlled, cross-over trial. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 706-714.	0.7	41
68	Adaptive graph-based multiple testing procedures. <i>Pharmaceutical Statistics</i> , 2014, 13, 345-356.	1.3	15
69	Maximum type I error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications. <i>Biometrical Journal</i> , 2014, 56, 614-630.	1.0	20
70	One-year evaluation of two hybrid composites placed in a randomized-controlled clinical trial. <i>Dental Materials</i> , 2014, 30, 824-838.	3.5	10
71	Lithium in the public water supply and suicide mortality in Texas. <i>Journal of Psychiatric Research</i> , 2013, 47, 407-411.	3.1	88
72	Modified solid-phase alloantibody detection for improved crossmatch prediction. <i>Human Immunology</i> , 2013, 74, 32-40.	2.4	21

#	ARTICLE	IF	CITATIONS
73	Health-related quality of life of long-term survivors of intensive care: changes after intensive care treatment. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 624-632.	1.9	2
74	Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. <i>Journal of Hepatology</i> , 2011, 54, 89-97.	3.7	39
75	Role of modeling and simulation in pediatric investigation plans. <i>Paediatric Anaesthesia</i> , 2011, 21, 214-221.	1.1	70
76	Comparison of three separate antiadhesive barriers for intraperitoneal onlay mesh hernia repair in an experimental model. <i>British Journal of Surgery</i> , 2011, 98, 442-449.	0.3	40
77	Selection and bias – Two hostile brothers. <i>Statistics in Medicine</i> , 2010, 29, 1-13.	1.6	69
78	Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 39-48.	1.9	101
79	A double-blind, randomized, placebo-controlled trial of intravenous l-ornithine-l-aspartate on postural control in patients with cirrhosis. <i>Liver International</i> , 2010, 30, 574-582.	3.9	31
80	Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 277-291.	46.4	127
81	Cytotoxic effects of dental bonding substances as a function of degree of conversion. <i>Dental Materials</i> , 2009, 25, 232-239.	3.5	55
82	Cytotoxicity of four categories of dental cements. <i>Dental Materials</i> , 2009, 25, 360-368.	3.5	80
83	The impact of colony-stimulating factor-1 on fracture healing: An experimental study. <i>Journal of Orthopaedic Research</i> , 2009, 27, 36-41.	2.3	29
84	Adaptive designs for confirmatory clinical trials. <i>Statistics in Medicine</i> , 2009, 28, 1181-1217.	1.6	208
85	Optimal choice of the number of treatments to be included in a clinical trial. <i>Statistics in Medicine</i> , 2009, 28, 1321-1338.	1.6	15
86	Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score. <i>European Journal of Clinical Investigation</i> , 2009, 39, 65-71.	3.4	15
87	The Distillation of "VISCI": Towards a Better Identification of Suicidal Inmates. <i>Suicide and Life-Threatening Behavior</i> , 2009, 39, 376-385.	1.9	7
88	The assessment of quality of life in a trial on lightweight mesh fixation with fibrin sealant in transabdominal preperitoneal hernia repair. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2008, 12, 499-505.	2.0	40
89	Adaptive Dunnett tests for treatment selection. <i>Statistics in Medicine</i> , 2008, 27, 1612-1625.	1.6	89
90	Combination of anorganic bovine-derived hydroxyapatite with binding peptide does not enhance bone healing in a critical-size defect in a rabbit model. <i>Journal of Orthopaedic Research</i> , 2008, 26, 759-763.	2.3	23

#	ARTICLE	IF	CITATIONS
91	MCP2007 – 5th International Conference on Multiple Comparison Procedures. Biometrical Journal, 2008, 50, 633-635.	1.0	3
92	Cytotoxicity and shear bond strength of four orthodontic adhesive systems. European Journal of Orthodontics, 2008, 30, 495-502.	2.4	25
93	Functional Recovery at a Minimum of 2 Years After Multiple Injury – Development of an Outcome Score. Journal of Trauma, 2008, 65, 799-808.	2.3	18
94	Suicide prevention in correctional institutions: The significance of solitary cell accommodation. International Journal of Prisoner Health, 2007, 3, 225-232.	0.9	4
95	Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials. Journal of Biopharmaceutical Statistics, 2007, 17, 965-995.	0.8	174
96	The scientific work of Peter Bauer. Biometrical Journal, 2007, 49, 651-653.	1.0	2
97	An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transplantation, 2007, 13, 1174-1180.	2.4	216
98	Multiplicity and flexibility in clinical trials. Pharmaceutical Statistics, 2007, 6, 205-216.	1.3	46
99	Characteristics of polytrauma patients between 1992 and 2002: What is changing?. Injury, 2007, 38, 1059-1064.	1.7	38
100	Cytotoxicity of resin composites as a function of interface area. Dental Materials, 2007, 23, 1438-1446.	3.5	32
101	The reassessment of trial perspectives from interim data – a critical view. Statistics in Medicine, 2006, 25, 23-36.	1.6	95
102	Estimation in flexible two stage designs. Statistics in Medicine, 2006, 25, 3366-3381.	1.6	65
103	Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts. Biometrical Journal, 2006, 48, 623-634.	1.0	235
104	An Adaptive Hierarchical Test Procedure for Selecting Safe and Efficient Treatments. Biometrical Journal, 2006, 48, 663-678.	1.0	17
105	Cytotoxicity of a calcium aluminate cement in comparison with other dental cements and resin-based materials. Acta Odontologica Scandinavica, 2006, 64, 1-8.	1.6	27
106	Geriatric polytrauma. Wiener Klinische Wochenschrift, 2005, 117, 145-149.	1.9	23
107	Testing and estimation in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine, 2005, 24, 3697-3714.	1.6	194
108	Effect of Information on Reported Adverse Events in a Placebo-Controlled Trial. Drug Safety, 2005, 28, 81-87.	3.2	4

#	ARTICLE	IF	CITATIONS
109	IFN- $\gamma$ enhanced allergen penetration across respiratory epithelium augments allergic inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 973-981.	2.9	38
110	Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 347-354.	2.9	147
111	Suicide in custody. <i>British Journal of Psychiatry</i> , 2004, 185, 494-498.	2.8	105
112	Transjugular intrahepatic portosystemic shunt in Vienna – A decade later. <i>Wiener Klinische Wochenschrift</i> , 2004, 116, 608-613.	1.9	7
113	Reliability of a standardized reading chart system: variance component analysis, test-retest and inter-chart reliability. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2004, 242, 31-39.	1.9	89
114	Conditional Rejection Probabilities of Student's t-test and Design Adaptations. <i>Biometrical Journal</i> , 2004, 46, 389-403.	1.0	30
115	Reading performance depending on the type of cataract and its predictability on the visual outcome. <i>Journal of Cataract and Refractive Surgery</i> , 2004, 30, 1259-1267.	1.5	37
116	Do monthly or seasonal variations exist in suicides in a high-risk setting?. <i>Psychiatry Research</i> , 2004, 121, 263-269.	3.3	13
117	Effects of a Femoral Shaft Fracture on Multiply Injured Patients with a Head Injury. <i>World Journal of Surgery</i> , 2003, 27, 365-369.	1.6	9
118	Longevity of direct resin composite restorations in posterior teeth: a review. <i>Clinical Oral Investigations</i> , 2003, 7, 63-70.	3.0	291
119	Cytotoxic effects of packable and nonpackable dental composites. <i>Dental Materials</i> , 2003, 19, 382-392.	3.5	62
120	Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. <i>Hepatology</i> , 2003, 38, 1043-1050.	7.3	160
121	Improved Repeated Confidence Bounds in Trials with a Maximal Goal. <i>Biometrical Journal</i> , 2003, 45, 311-324.	1.0	29
122	Fixation of femoral fractures in multiple-injury patients with combined chest and head injuries. <i>ANZ Journal of Surgery</i> , 2003, 73, 1018-1021.	0.7	18
123	Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. <i>Gut</i> , 2003, 52, 879-885.	12.1	244
124	Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. <i>Hepatology</i> , 2003, 38, 1043-1050.	7.3	90
125	Vascular endothelial growth factor (VEGF) and discrimination between abnormal intrauterine and ectopic pregnancy. <i>Human Reproduction</i> , 2002, 17, 3231-3234.	0.9	17